Categories
Change Password!
Reset Password!
Phentermine’s integration with behavioral therapy (psychological intervention) shows transformative weight loss for those struggling to see results.
For the first time, a revolutionary study revealed that combining anti-obesity medicines with behavioral treatment (BT) can catapult weight loss in individuals who’ve earlier struggled to see outcomes from usual BT methods. This compelling new randomized controlled trial shines a spotlight on the 35-50% of patients who fail to meet their weight loss goals with BT alone, presenting them as a powerful new tool for success.
The study focused on adults with a body mass index (BMI) of 31 or higher, or 28 or higher with obesity-connected comorbidities, who underwent an initial BT for 4 weeks. Participants who failed to lose at least 2% of their starting weight during this time (referred to as "early non-responders") were then randomized into two groups. One group received BT together with a placebo, while the other group was given BT combined with phentermine, a well-known anti-obesity medicine.
After 24 weeks, people in the group that received BT plus phentermine experienced a weight loss reduction of 5.9%, compared to just 2.8% in the other (placebo) group. This marked a pivotal improvement of 3.1% (P=0.003), inferring that the addition of anti-obesity medicines can make a profound difference for those who originally struggled to lose weight with just BT.
This leap forward could revolutionize obesity treatment, providing a powerful new option for those who’ve toiled with behavioral interventions alone.
Nature Medicine
Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial
Jena S. Tronieri et al.
Comments (0)